Patients in recent international adjuvant trials like MONARCH-E, NATALI, and LADERA have a significantly higher baseline risk of recurrence compared to those in US-centric studies like TaylorX. Three-year event rates are two to four times higher, which is critical context for applying these findings and assessing the cost-benefit of new, toxic therapies for average-risk patients.

Despite enthusiasm, Dr. Gross cautions against universally adopting neoadjuvant immunotherapy for advanced CSCC. He argues its safety and superiority over standard upfront surgery are unknown, underscoring the critical need for phase 3 randomized trials to validate this approach before it becomes a standard of care.

For patients with borderline resectable CSCC, upfront anti-PD-1 therapy is used not just for efficacy but as a strategy to preserve function. This approach can prevent life-altering surgeries, such as eye removal, offering a chance for both cure and improved quality of life.

Clinicians should not treat all immunosuppression as a monolithic high-risk factor for skin cancer. Recent data show that lymphoproliferative disorders like chronic lymphocytic leukemia (CLL) pose a much greater risk for aggressive CSCC than many modern solid organ transplant medication regimens.

Among solid organ transplant patients, who are already at high risk for skin cancer, heart transplant recipients are at the greatest risk. This is specifically due to the type and duration of immunosuppressive drugs required to prevent organ rejection, highlighting a critical sub-population for dermatologic surveillance.

The next frontier in CSCC isn't just about new drugs, but about optimizing existing ones. A key research area is determining the minimum number of immunotherapy doses required for an optimal response—potentially just one or two—to limit toxicity, reduce treatment burden, and personalize care for high-risk patients.

Contrary to the common assumption that metastatic disease is the primary cause of cancer-related death, a large international study on CSCC found that two-thirds of patients died from local-regional uncontrolled progression. This highlights the critical importance of effective local control strategies.

The varied manifestations of advanced CSCC—local, nodal, or perineural—create a heterogeneous patient population. This complexity has led to its exclusion from major cancer databases and made it a "blind spot" for industry, slowing research despite the disease's prevalence.

CLL-associated immunosuppression dramatically increases the risk and aggressiveness of skin cancers. This risk is not mitigated by novel therapies, and in some cases, the secondary skin malignancy can become a greater threat to a patient's life than their underlying CLL.